Qilu Pharmaceutical Co., Ltd.
- Biotech or pharma, therapeutic R&D
- CMO, CRO
- Investor (buy-side or sell-side research)
Qilu Pharmaceutical is a top 3 pharma company in China. We cover diverse therapeutic areas with a focus on oncology, cardiovascular and metabolic diseases, immunology, infectious diseases, and CNS diseases.
In the United States, Qilu has 34 approved ANDAs, 9 Tentatively Approved ANDA's, and a a pipeline of over 50 generic and biosimilar products in R&D.
Qilu is also developing an innovative pipeline of various biologic modalities (monoclonal/bispecific/trispecific antibodies, ADCs, fusion proteins) and small molecules for oncology, immunology, cardiovascular, and metabolic diseases from IND-enabling to late clinical stage. These assets are available for global or ex-China licensing.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}